Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 914 Shares of Stock

Natera, Inc. (NASDAQ:NTRAGet Free Report) CFO Michael Burkes Brophy sold 914 shares of Natera stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $90.42, for a total value of $82,643.88. Following the transaction, the chief financial officer now owns 72,024 shares in the company, valued at approximately $6,512,410.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

  • On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The shares were sold at an average price of $88.36, for a total transaction of $249,705.36.
  • On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The shares were sold at an average price of $70.03, for a total transaction of $2,383,050.87.
  • On Thursday, February 1st, Michael Burkes Brophy sold 22,281 shares of Natera stock. The shares were sold at an average price of $67.73, for a total transaction of $1,509,092.13.
  • On Monday, January 29th, Michael Burkes Brophy sold 3,235 shares of Natera stock. The shares were sold at an average price of $65.09, for a total transaction of $210,566.15.
  • On Tuesday, January 23rd, Michael Burkes Brophy sold 2,202 shares of Natera stock. The shares were sold at an average price of $65.86, for a total transaction of $145,023.72.

Natera Price Performance

NTRA stock opened at $91.46 on Friday. The business has a 50 day moving average price of $78.46 and a 200 day moving average price of $61.25. The stock has a market cap of $11.04 billion, a price-to-earnings ratio of -24.13 and a beta of 1.39. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $96.24. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37.

Natera (NASDAQ:NTRAGet Free Report) last posted its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The firm had revenue of $311.11 million during the quarter, compared to analysts’ expectations of $300.38 million. Equities research analysts anticipate that Natera, Inc. will post -2.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. TD Cowen boosted their price objective on shares of Natera from $82.00 to $87.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. BTIG Research lifted their target price on Natera from $75.00 to $85.00 and gave the company a “buy” rating in a research report on Friday, December 29th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research report on Thursday, March 14th. Wolfe Research assumed coverage on Natera in a research report on Wednesday, December 13th. They issued an “outperform” rating and a $70.00 target price for the company. Finally, Guggenheim assumed coverage on Natera in a research report on Thursday, December 14th. They issued a “buy” rating and a $70.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $78.36.

View Our Latest Stock Report on Natera

Institutional Investors Weigh In On Natera

Large investors have recently modified their holdings of the stock. RiverPark Advisors LLC purchased a new stake in shares of Natera during the fourth quarter worth approximately $27,000. Principal Securities Inc. acquired a new position in Natera during the fourth quarter worth $32,000. Kayne Anderson Rudnick Investment Management LLC acquired a new position in Natera during the second quarter worth $29,000. Pinebridge Investments L.P. acquired a new position in Natera during the second quarter worth $33,000. Finally, Oliver Lagore Vanvalin Investment Group grew its holdings in Natera by 109.3% during the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after acquiring an additional 389 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Company Profile

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Featured Stories

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.